CGAS and cancer: By discriminating large (i.e., >10,000 bp) cfDNA associated with necrosis from the short (i.e., 180 bp) ones associated with tumor apoptosis with immunogenic response via STING-cGAS, it paves the way for a qualitative and quantitative monitoring of cancer patients.